DM.V - Datametrex AI Limited
| Previous Close | 0.1300 |
| Open | 0.1350 |
| Bid | 0.1250 x 0 |
| Ask | 0.1300 x 0 |
| Day's Range | 0.1300 - 0.1400 |
| 52 Week Range | 0.0100 - 0.2200 |
| Volume | 1,045,084 |
| Avg. Volume | 5,030,769 |
| Market Cap | 30.381M |
| Beta (5Y Monthly) | 4.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0120 |
| Earnings Date | Aug. 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Datametrex Enters Strategic Agreement to Help Provide for Processing of COVID-19 Tests for Canadian Companies
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that is has signed a Strategic Partnership and Development Agreement (the “Agreement”) with Transpharm Canada Inc. (“TCI”). Under the term of the Agreement TCI will work with Datametrex on scoping out services and providing access to its 25,000 sq. ft state-of-the-art testing facility located in Toronto, ON, to provide support and testing services for COVID-19 testing kits that Datametrex has in its portfolio. Datametrex will be providing the COVID-19 test kits.
- GlobeNewswire
Datametrex Adds Pharmacologist Alex MacGregor to the Medical Advisory Board
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that President and Dean of the Toronto Institute of Pharmaceutical Technology (“TIPT”) and Clinical Pharmacologist, Dr. Alexander MacGregor, Ph.D., a, has consented to join the Company's Medical Advisory Board. The Company is also in discussion with Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology to provide lab testing services using there fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility located in Toronto, ON, Canada.
- CNW Group
IIROC Trading Resumption - DM
VANCOUVER , May 15, 2020 /CNW/ - Trading resumes in: Company: Datametrex AI Limited TSX-Venture Symbol: DM (all issues) Resumption (ET): 11:00 AM IIROC can make a decision to impose a temporary suspension ...
- GlobeNewswire
Datametrex Announces Sale of COVID-19 Test Kit to Canadian Mining Company
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce it has received a purchase order for (the “PO”) COVID-19 test kits from a Canadian based mining company with over 4,000 employees in multiple jurisdictions outside of Canada. Under the terms of the PO, Datametrex will sell to the purchaser an initial 10,000 units of COVID-19 Detection Kits, comprising of 10,000 3 mL Universal Transport Medium (UTM®) Sterile Swabs with 16x100mm Skirted Tubes with Plastic Red Capture Caps, and 1 Real-Time PCR Detection System machine to analyze the samples. Datametrex anticipates that it will have little or no upfront costs associated with the sale of these test kits.
- GlobeNewswire
Datametrex Obtains Rights to Sell Health Canada Approved COVID-19 Test Kit
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has secured non-exclusive rights to COVID-19 test kits with Health Canada (“HC”) approval, Kingdom of Saudi Arabia, Saudi Food & Drug Authority (“SFDA”) approval, and CE marking certification (“CE”) for European Economic Area (“EEA”) countries, which covers the 27 member states of the EU, the 4 members of EFTA, plus Turkey and the United Kingdom under Brexit. The latest, and fourth kit to be added by Datametrex to distribute is the 1copy™ COVID-19 qPCR Multi Kit (“qPCR kit”), which is Health Canada approved with Authorization Reference Number 312777, Device ID 1020660 and Model No. M22MD100.
- GlobeNewswire
Datametrex Obtains Rights to Sell COVID-19 Tests From Two Additional South Korean Manufacturers
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has secured non-exclusive rights to sell COVID-19 test kits from two additional South Korean manufacturers, including a kit that is U.S. Food & Drug Administration (“FDA”) approved under Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices (“EUA”) for the United States, and CE marking certification (“CE”) for European Economic Area (“EEA”) countries, which covers the 27 member states of the EU, the 4 members of EFTA, plus Turkey and the United Kingdom under Brexit. According to each of the manufacturers, these test kits made are both Nucleic Acid based, which Health Canada is prioritizing the review of.
- GlobeNewswire
Datametrex Appoints Todd Shapiro As New Board Of Director And Hosts Investor Update
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce Todd Shapiro has joined the board of director. Todd currently sits on the Board of Directors for Red Light Holland, JamStacked and Mogul Productions. Janeen Stodulski stepped down from the board to make a seat available for Todd to join the Board.
- GlobeNewswire
Datametrex Appoints Paul Haber as Director and Insider Exercising Options and Warrants
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that Mr. Paul Haber,CPA, CA, C.Dir., has joined the Board of Directors. Mr. Haber has been involved in corporate finance and capital markets for over 25 years as an banker, investor and entrepreneur. Mr. Haber started his career with Coopers & Lybrand,now PwC LLP.
- GlobeNewswire
Datametrex Announces Insider Option Exercise
TORONTO, April 27, 2020 -- Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that certain employees, management, and.
- GlobeNewswire
Datametrex Awarded $217,000 by Department of National Defence for Completion of Phase 2 of Innovation Program
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that the Department of National Defence approved the Company’s completion of the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security (IDEaS) program. The Company will continue to work on phase 3 of the program to further develop Nexalogy SMART, Social Media Automated Reporting Technologies. Due to confidentiality requirements, the Company is not permitted to provide additional details about the nature of the work being performed for the Department of National Defence.
- GlobeNewswire
Datametrex Provides Update On Health Canada Submission & Welcomes Advisors
Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF ) wishes to provide additional specifics on the previously announced news release regarding acquiring the rights to import COVID-19 test kits from South Korea. An application for approval was made to Health Canada under the Fast-Track program on April 9th, 2020. As part of the submission, the Company has submitted a Medical Devices Interim Order Request Form under Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act signed by the Minister of Health on March 18, 2020.
- Newsfile
Graph Blockchain Applauds Shareholder Datametrex AI Limited for Their Response to the Covid-19 Pandemic
Toronto, Ontario--(Newsfile Corp. - April 17, 2020) - Graph Blockchain Inc. (CSE: GBLC) ("Graph" or "Company") applauds Datametrex Limited (TSXV: DM) (FSE: D4G) (minority interest shareholder of 26% of the Company) for securing the rights to import COVID-19 detection kit into Canada and other countries around the globe. See Press Release dated April 16, 2020 Health Canada must approve these COVID-19 test kits before they can be used in Canada. Datametrex is currently working ...
